USPTO serial 97347615
RNATE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- CREEF, DAVIS W
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RNATE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Holly Springs, NC, US
Holly Springs, NC, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nancy Sabarra
Nancy Sabarra FROSS ZELNICK LEHRMAN & ZISSU, P.C.151 WEST 42ND ST., 17TH FL.NEW YORK, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use | ACTIVE | — |
| 005 | Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells | ACTIVE | — |
| 042 | Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines | ACTIVE | — |
| 044 | Medical services; medical information; providing a website featuring medical information | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Seqirus Inc.
- Other trademarks owned by Seqirus Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named RNATE
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 10, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 10, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 29, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 29, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 28, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 5, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 4, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 27, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 26, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 26, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 26, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 4, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 3, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 2, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 2, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 13, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 6, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 6, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 6, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 21, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 19, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 19, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 19, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 4, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 9, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 9, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 19, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 5, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 5, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 5, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 5, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 5, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 22, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 21, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 21, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 27, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 27, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 27, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 23, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 11, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 8, 2022 | NWAP | NEW APPLICATION ENTERED | — |